PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,208 stories, page 371 of 671

Advanced search
🌍discoverynews.google.comTier 3 · Aggregated media

Sun Pharma shareholders approve all resolutions at 34th AGM

scanx.tradeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Scientific advisory board tasked with setting path for fragile skin treatment

epidermolysisbullosanews.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Drug Repurposing’s Next Challenge: Turning Discoveries Into Treatments

Inside Precision MedicineOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Why Drug Safety Has Become India's Next Pharmaceutical Imperative

BioSpectrum IndiaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Janus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

RTW Biotech Opportunities Ltd USD Revenue Breakdown – FWB:0BM

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Over 1,500 experts attended the Hanoi Hospital Pharmaceutical Science Conference (expanded) in Nghe An.

Vietnam.vnOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Fluctuations in entrance exam scores for medical and pharmaceutical schools in the North over the past 3 years, with "hot" majors exceeding 27 points.

Vietnam.vnOriginal source
🌍Regulatorywho.intTier 1 · Regulatory source

Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo

WHO Disease Outbreak NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis

TradingKeyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Axiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

VYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in India

The Eastern HeraldOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Moleculin Biotech (MBRX US): Synthetic Expert Call Transcript (01 Aug 2026)

SmartkarmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Sichuan Kelun Biotech (SEHK:6990) Wins Priority Review For Sixth Sac TMT Indication

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Teva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Avidity Partners Management LP

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Collegium Pharmaceutical (COLL.US) will release its earnings report before the market opens on August 6.

google_newsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBITDA forward of Lushang Freda Pharmaceutical Co., Ltd. Class A – SSE:600223

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’

StocktwitsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Routine Health Data Is Outperforming Trial Data for AI Training. The FDA Hasn’t Caught Up.

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Is Reta Safe?

Yahoo CreatorsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Vidipha Central Pharmaceutical JSC Revenue Breakdown – HOSE:VDP

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Keros Receives $20M Milestone as Elritercept Phase 3 Trial Enrolls First Patient

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Moleculin Biotech updates Annamycin data, prices stock offering at $0.75

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Latest Glp 1 Weight Loss Drug News Today: Breakthroughs And Updates [B80XXaMIG4d]

Diario ASOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Radiopharm reports positive phase 2b results for RAD 101 imaging agent

Investing.com UKOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

China recruits 105 top US scientists as biotech race intensifies

e.vnexpress.netOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Why Drug Safety Has Become India's Next Pharmaceutical Imperative

BioSpectrum IndiaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Crackdown: Hotel Associations Urge Due Process, Oppose Public Naming Before Legal Proceedings End

PUNE PULSEOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA crackdown: Why hotel bodies want Modi, Fadnavis to step in

The Indian ExpressOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

How Investors Are Reacting To Disc Medicine (IRON) Balancing Larger Losses With APOLLO Phase 3 FDA Alignment

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXA

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy?

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Mumbai’s elite clubs lose FSSAI licences after FDA crackdown

Hotelier IndiaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Bombay HC slams FDA over "untrue" clean chit to Mantralaya canteen after lawyers' surprise inspection uncovers hygiene lapses

Bar and BenchOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Novo Nordisk's August Reckoning: Courtroom Battles and a Failed Heart Drug Converge

AD HOC NEWSOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

CREATE medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license agreement with Monash University

Monash UniversityOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Daily Brief Health Care: Moleculin Biotech , Attovia Therapeutics, BioStem Technologies , Harbin Yuyantang Traditional Chinese Medicine Outpatient Group, Braveheart Bio, Vogenx, Apnimed and more

SmartkarmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

IPO Databook: Moleculin Biotech (MBRX US) - Jul 2026

SmartkarmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of Samil Pharmaceutical Co., Ltd. – KRX:000520

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BlackRock, Inc. Trims Alumis Inc (ALMS) Stake Amid Biotech's Met

GuruFocusOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status

Investing.com UKOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Novo Nordisk misses key heart outcomes in Phase 3, shares sink 10% - CHOSUNBIZ

ChosunbizOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

B.Riley initiates 4D Molecular Therapeutics stock coverage with buy rating

Investing.com UKOriginal source
🌍Industrymonashhealth.orgTier 1 · Company source

Transforming Tracheostomy Education – From Local Innovation to National Impact

Monash HealthOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Medicines, Misleading Ads On Tukaram Mundhe's Radar? Maharashtra FDA Chief Says...

NDTV ProfitOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA panel backs unapproved peptides despite safety concerns

Drug Discovery NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

코메디닷컴Original source
🌍discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services (WST) Raised Guidance, Is It Still 16% Undervalued?

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Doctors warn against 'most powerful weight-loss jab ever as users exploit legal loophole

LADbibleOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI

Proactive financial newsOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Editorial] Indigenous-led cancer control

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Corrections] Correction to Lancet Oncol 2026; 27: 452–60

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] Risks of modelling cancer outcomes when no data exist – Authors' reply

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Cretostimogene grenadenorepvec: promise beyond response

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] Risks of modelling cancer outcomes when no data exist

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Chest wall radiotherapy in SUPREMO: a quality-of-life perspective

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Chemoradiotherapy intensification in rectal cancer: lessons from the ARISTOTLE trial

Lancet OncologyOriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: A comprehensive investigation of Pseudomonas quorum sensing regulatory relationships and the consequences on quorum sensing inhibitors in complex communities

Recipient: MASSACHUSETTS GENERAL HOSPITAL. Award amount: 389004.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP)

Recipient: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE. Award amount: 42995.

NIH RePORTEROriginal source